Literature DB >> 9204065

Antiphospholipid syndrome and the skin.

G E Gibson1, W P Su, M R Pittelkow.   

Abstract

The antiphospholipid syndrome is an acquired multisystem disorder of hypercoagulation, which may be primary or secondary to underlying diseases. Serologic markers for the syndrome are the lupus anticoagulant and anticardiolipin antibodies. Clinical features include recurrent thrombotic events (arterial or venous), repeated fetal loss, and thrombocytopenia. Cutaneous manifestations may occur as the first sign of antiphospholipid syndrome. These include livedo reticularis, necrotizing vasculitis, livedoid vasculitis, thrombophlebitis, cutaneous ulceration and necrosis, erythematous macules, purpura, ecchymoses, painful skin nodules, and subungual splinter hemorrhages. Antiphospholipid syndrome may also be associated rarely with anetoderma, discoid lupus erythematosus, cutaneous T-cell lymphoma, or disorders that closely resemble Sneddon or Degos syndromes. Noninflammatory vascular thrombosis is the most frequent histopathologic feature observed. Prophylaxis and treatment of thrombosis in patients with antiphospholipid syndrome relies principally on anticoagulant and antiplatelet agents.

Entities:  

Mesh:

Year:  1997        PMID: 9204065     DOI: 10.1016/s0190-9622(97)80283-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  12 in total

1.  [Special aspects for preventing thromboembolism in surgical dermatology].

Authors:  R Rompel; E Rabe; I Hackert; G Sebastian
Journal:  Hautarzt       Date:  2002-03       Impact factor: 0.751

Review 2.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

3.  Leg ulcers in the antiphospholipid syndrome may be considered as a form of pyoderma gangrenosum and they respond favorably to treatment with immunosuppression and anticoagulation.

Authors:  Carlos A Cañas; Carlos E Durán; Juan C Bravo; Dora E Castaño; Gabriel J Tobón
Journal:  Rheumatol Int       Date:  2010-03-28       Impact factor: 2.631

Review 4.  [Lupus erythematosus. Wide range of symptoms through clinical variation, associated diseases and imitators].

Authors:  E Aberer
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

Review 5.  Generalized Anetoderma after Intravenous Penicillin Therapy for Secondary Syphilis in an HIV Patient.

Authors:  Jason Emer; Daniel Roberts; Harleen Sidhu; Robert Phelps; Herbert Goodheart
Journal:  J Clin Aesthet Dermatol       Date:  2013-08

Review 6.  Vasculitis in the connective tissue diseases.

Authors:  D Alarcón-Segovia
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 7.  Skin Conditions and Movement Disorders: Hiding in Plain Sight.

Authors:  Kristina Kulcsarova; Janette Baloghova; Jan Necpal; Matej Skorvanek
Journal:  Mov Disord Clin Pract       Date:  2022-03-24

8.  Primary antiphospholipid syndrome with and without Sneddon's syndrome.

Authors:  Cezar Augusto Muniz Caldas; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

9.  [Lucio phenomenon. Vasculitis or occlusive vasculopathy?].

Authors:  L Azulay-Abulafia; L Pereira Spinelli; D Hardmann; B Kawa Kac; R A Levy; C Talhari; T Ruzicka
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

10.  Response to rituximab in a case of lupus associated digital ischemia.

Authors:  Orhan Küçükşahin; Nurşen Düzgün; Alexis K Okoh; Emre Kulahçioglu
Journal:  Case Rep Rheumatol       Date:  2014-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.